The present invention relates to a pharmaceutical composition for treating a cancer comprising a crRNA and an endonuclease as active ingredients. The present invention may be tailored to the needs of patients or cell types by specifically treating cancer cells based on the specific binding property of DNA and RNA. The nuclease activity of the CRISPR PLUS system according to the present invention can be activated by the binding of crRNA to a gene specifically present in cancer cells. Therefore, the cancer treatment effect of the present invention is more specific than other anti-cancer agents currently developed.本發明係有關一用於治療癌症之包含crRNA及核酸內切酶作為活性成分的藥學組成物。本發明可依據病患或細胞類型之需求量身訂制，利用基於DNA與RNA之特異性結合性質而特異地治療癌細胞。本發明CRISPR PLUS系統之核酸酶活性可藉由將crRNA結合至特異地存在於癌細胞之基因而活化。因此，本發明之癌症治療效果比目前開發的其他抗癌劑更具特異性。
